Although the mechanisms by which PTEN deletion might promote immune evasion are incompletely understood, recent studies in melanomas with PTEN loss have motivated clinical trials of specific PI3K inhibitors in combination with ICB [10,13]. Here, PTEN is linked to melanoma.